Dermata Financial Statements From 2010 to 2025

DRMA Stock  USD 0.69  0  0.22%   
Dermata Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dermata Therapeutics' valuation are provided below:
Market Capitalization
4.2 M
Earnings Share
(1.42)
We have found one hundred three available fundamental signals for Dermata Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Dermata Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of July 22, 2025, Market Cap is expected to decline to about 2.3 M. The current year's Enterprise Value is expected to grow to about (1.2 M)
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 237.1 K, Depreciation And Amortization of 13.1 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0014. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Dermata Stock
Check out the analysis of Dermata Therapeutics Correlation against competitors.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

Dermata Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM3.5 M3.6 M
Slightly volatile
Short and Long Term Debt Total2.7 M4.1 M2.1 M
Slightly volatile
Other Current Liabilities758.7 K1.2 M674.5 K
Pretty Stable
Total Current Liabilities1.5 MM1.8 M
Very volatile
Current Deferred Revenue124 K139.5 K152.1 K
Slightly volatile
Accounts Payable573.4 K808 K421 K
Slightly volatile
Cash5.5 M3.2 M3.4 M
Slightly volatile
Long Term Debt442.6 K497.9 K542.8 K
Slightly volatile
Cash And Short Term Investments5.5 M3.2 M3.4 M
Slightly volatile
Common Stock Shares Outstanding1.6 M1.5 M307.8 K
Slightly volatile
Liabilities And Stockholders Equity6.6 M3.5 MM
Slightly volatile
Non Current Liabilities Total1.2 B1.2 B197.2 M
Slightly volatile
Other Current Assets471 K372.3 K231.4 K
Slightly volatile
Other Stockholder Equity70.7 B67.3 B8.7 B
Slightly volatile
Total Liabilities1.6 MM2.1 M
Slightly volatile
Net Invested Capital1.5 M1.6 M2.3 M
Slightly volatile
Property Plant And Equipment Gross92.5 K88.1 K30.6 K
Slightly volatile
Short and Long Term Debt2.4 M4.1 M1.7 M
Slightly volatile
Total Current AssetsM3.5 M3.6 M
Slightly volatile
Short Term Debt2.4 M4.1 M1.7 M
Slightly volatile
Common Stock2392521.6 M
Slightly volatile
Property Plant Equipment258290316
Slightly volatile
Non Currrent Assets Other44.6 K50.1 K54.7 K
Slightly volatile
Capital Stock239252757
Slightly volatile
Net Receivables8.4 K7.5 K11.8 K
Slightly volatile
Short Term Investments2.5 B2.8 B3.1 B
Slightly volatile

Dermata Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization13.1 M12.5 M2.1 M
Slightly volatile
Interest Expense111.4 K57.2 K190.4 K
Slightly volatile
Selling General Administrative4.5 B4.3 B554.2 M
Slightly volatile
Other Operating Expenses7.3 M9.2 M5.6 M
Slightly volatile
Research Development8.6 B8.2 B1.1 B
Slightly volatile
Cost Of Revenue275290963
Slightly volatile
Total Operating Expenses8.4 M12.5 M5.9 M
Slightly volatile
Interest Income196.7 K225.8 K93.5 K
Slightly volatile
Selling And Marketing Expenses3.2 B3.6 B3.9 B
Slightly volatile

Dermata Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.2 M7.4 M2.7 M
Slightly volatile
Depreciation17.1 K16.2 K5.6 K
Slightly volatile
Issuance Of Capital StockM6.9 M5.9 M
Pretty Stable
Total Cash From Financing Activities7.7 M6.9 M5.8 M
Slightly volatile
End Period Cash Flow5.5 M3.2 M3.4 M
Slightly volatile
Dividends Paid1.8 M2.1 M2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables440.7 K753.3 K390.9 K
Slightly volatile
Payables Turnover0.00390.00360.0037
Slightly volatile
Cash Per Share1.962.06676.9646
Slightly volatile
Days Payables Outstanding83.6 K106.4 K98.2 K
Slightly volatile
Income Quality1.00.90850.8702
Slightly volatile
Current Ratio3.11.79132.3216
Slightly volatile
Interest Debt Per Share0.09570.12.3205
Slightly volatile
Debt To Assets5.535.272.5274
Slightly volatile
Days Of Payables Outstanding83.6 K106.4 K98.2 K
Slightly volatile
Ebt Per Ebit1.10.9821.0395
Slightly volatile
Quick Ratio3.11.79132.3216
Slightly volatile
Net Income Per E B T1.141.161.0568
Pretty Stable
Cash Ratio2.851.60262.1637
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9813
Slightly volatile
Debt Ratio5.535.272.5274
Slightly volatile

Dermata Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 M2.4 M464 M
Slightly volatile

Dermata Fundamental Market Drivers

Cash And Short Term Investments3.2 M

Dermata Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Dermata Therapeutics Financial Statements

Dermata Therapeutics stakeholders use historical fundamental indicators, such as Dermata Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Dermata Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Dermata Therapeutics' assets and liabilities are reflected in the revenues and expenses on Dermata Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue139.5 K124 K
Cost Of Revenue 289.80  275.31 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:
Check out the analysis of Dermata Therapeutics Correlation against competitors.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.42)
Return On Assets
(0.96)
Return On Equity
(2.06)
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.